(2R,7R)-Diaminooctanedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide)

ID: ALA4456247

Chembl Id: CHEMBL4456247

PubChem CID: 155524657

Max Phase: Preclinical

Molecular Formula: C80H124N26O16

Molecular Weight: 1706.04

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(C)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](N)CCCC[C@@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O

Standard InChI:  InChI=1S/C80H124N26O16/c1-43(2)37-61(73(119)97-55(13-7-33-93-77(85)86)69(115)101-59(65(83)111)39-45-17-25-49(107)26-18-45)105-71(117)57(15-9-35-95-79(89)90)99-75(121)63(41-47-21-29-51(109)30-22-47)103-67(113)53(81)11-5-6-12-54(82)68(114)104-64(42-48-23-31-52(110)32-24-48)76(122)100-58(16-10-36-96-80(91)92)72(118)106-62(38-44(3)4)74(120)98-56(14-8-34-94-78(87)88)70(116)102-60(66(84)112)40-46-19-27-50(108)28-20-46/h17-32,43-44,53-64,107-110H,5-16,33-42,81-82H2,1-4H3,(H2,83,111)(H2,84,112)(H,97,119)(H,98,120)(H,99,121)(H,100,122)(H,101,115)(H,102,116)(H,103,113)(H,104,114)(H,105,117)(H,106,118)(H4,85,86,93)(H4,87,88,94)(H4,89,90,95)(H4,91,92,96)/t53-,54-,55+,56+,57+,58+,59+,60+,61+,62+,63+,64+/m1/s1

Standard InChI Key:  HHGDUTJHZKFJND-IVCMQURDSA-N

Alternative Forms

  1. Parent:

    ALA4456247

    ---

Associated Targets(Human)

NPY4R Tchem Neuropeptide Y receptor type 4 (1071 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NPY1R Tchem Neuropeptide Y receptor type 1 (5019 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NPY2R Tchem Neuropeptide Y receptor type 2 (3731 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NPY5R Tchem Neuropeptide Y receptor type 5 (1834 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 1706.04Molecular Weight (Monoisotopic): 1704.9689AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Liu M, Mountford SJ, Richardson RR, Groenen M, Holliday ND, Thompson PE..  (2016)  Optically Pure, Structural, and Fluorescent Analogues of a Dimeric Y4 Receptor Agonist Derived by an Olefin Metathesis Approach.,  59  (13): [PMID:27295337] [10.1021/acs.jmedchem.6b00310]
2. Kuhn KK, Ertl T, Dukorn S, Keller M, Bernhardt G, Reiser O, Buschauer A..  (2016)  High Affinity Agonists of the Neuropeptide Y (NPY) Y4 Receptor Derived from the C-Terminal Pentapeptide of Human Pancreatic Polypeptide (hPP): Synthesis, Stereochemical Discrimination, and Radiolabeling.,  59  (13): [PMID:27223253] [10.1021/acs.jmedchem.6b00309]

Source